Tessonome

The relative absence of innovation set against a bloated cost structure has led to a rapid decline in value of large-cap pharmaceuticals, from nearly two-thirds of the market cap of health care in 2000 to less than one-third today.Over the past eight years, the pharmaceuticals sector has lost a stunning $593 billion (-65%) in market cap while the two sectors with innovation—bio tech and med tech—have each added $71 billion (+46%) and $19 billion (+6%) in market cap, respectively….Generic drugs have also fared well (+$27 billion or +139% in market cap) as generics represent a low-cost solution to high drug costs…

… did his conscience speak out loud to him?

Foto Tess Jungblut